Defining the Genomic Landscape of Diffuse Sclerosing Papillary Thyroid Carcinoma: Prognostic Implications of RET Fusions
Background Diffuse sclerosing papillary thyroid carcinoma (DSPTC) is an aggressive histopathologic subtype of papillary thyroid carcinoma. Correlation between genotype and phenotype has not been comprehensively described. This study aimed to describe the genomic landscape of DSPTC comprehensively us...
Gespeichert in:
Veröffentlicht in: | Annals of surgical oncology 2024-09, Vol.31 (9), p.5525-5536 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Background
Diffuse sclerosing papillary thyroid carcinoma (DSPTC) is an aggressive histopathologic subtype of papillary thyroid carcinoma. Correlation between genotype and phenotype has not been comprehensively described. This study aimed to describe the genomic landscape of DSPTC comprehensively using next-generation sequencing (NGS), analyze the prognostic implications of different mutations, and identify potential molecular treatment targets.
Methods
Tumor tissue was available for 41 DSPTC patients treated at Memorial Sloan Kettering Cancer Center between 2004 and 2021. After DNA extraction, NGS was performed using the Memorial Sloan Kettering Integrated Mutation Profiling of Actionable Cancer Targets platform, which sequences 505 critical cancer genes. Clinicopathologic characteristics were compared using the chi-square test. The Kaplan-Meier method and log-rank statistics were used to compare outcomes.
Results
The most common mutation was
RET
fusion, occurring in 32% (13/41) of the patients. Other oncologic drivers occurred in 68% (28/41) of the patients, including 8
BRAF
V600E
mutations (20%) and 4
USP8
mutations (10%), which have not been described in thyroid malignancy previously. Patients experienced
RET
fusion-positive tumors at a younger age than other drivers, with more aggressive histopathologic features and more advanced T stage (
p
= 0.019). Patients who were
RET
fusion-positive had a significantly poorer 5-year recurrence-free survival probability than those with other drivers (46% vs 84%;
p
= 0.003; median follow-up period, 45 months). In multivariable analysis,
RET
fusion was the only independent risk factor for recurrence (hazard ratio [HR], 7.69;
p
= 0.017).
Conclusion
Gene-sequencing should be strongly considered for recurrent DSPTC due to significant prognostic and treatment implications of
RET
fusion identification. The novel finding of
USP8
mutation in DSPTC requires further investigation into its potential as a driver mutation. |
---|---|
ISSN: | 1068-9265 1534-4681 1534-4681 |
DOI: | 10.1245/s10434-024-15500-9 |